Flinn I W, Lazarus H M
Johns Hopkins Oncology Center, Division of Hematologic Malignancies, Baltimore, MD 21231, USA.
Bone Marrow Transplant. 2001 Mar;27(6):565-9. doi: 10.1038/sj.bmt.1702857.
The introduction of monoclonal antibodies into the clinic has paved the way for new approaches to stem cell transplantation for patients with lymphoma. These approaches include the development of new high-dose regimens with radiolabeled antibodies, in vivo purging techniques with the unlabeled antibodies, and post-transplant adjuvant immunotherapy. Numerous trials have demonstrated the feasibility of these approaches. However, questions remain regarding the application of these antibodies including the ultimate efficacy. The recent results of the incorporation of monoclonal antibodies into stem cell transplantation and current research directions are reviewed.
单克隆抗体引入临床为淋巴瘤患者的干细胞移植新方法铺平了道路。这些方法包括开发含放射性标记抗体的新的高剂量方案、使用未标记抗体的体内净化技术以及移植后辅助免疫疗法。众多试验已证明这些方法的可行性。然而，关于这些抗体的应用仍存在问题，包括最终疗效。本文综述了将单克隆抗体纳入干细胞移植的最新结果及当前研究方向。
